What We Don't Learn from Clinical Trials in Epilepsy
Author:
Open Access
Abstract
Summary: The randomized, double‐blind trial design offers the most accurate data regarding the efficacy of antiepileptic treatments. However, translating the results of a trial into clinical care can be complex due to the intrinsic tension between the requirements for scientific methods that minimize systematic and random error, and the need for clinically relevant and generalizable data. The interpretation of the trial results is complicated further by the probable inaccuracy of self‐reported seizure rates and spontaneously reported adverse effects in most trials. Patient preference may be a feasible outcome measure that allows patient‐oriented validation of the results, and also inherently weighs the positive and negative effects of a treatment in a single endpoint.Keywords
This publication has 12 references indexed in Scilit:
- Outpatient Seizure IdentificationJournal Of Clinical Neurophysiology, 2001
- Outcomes Research: Measuring the End Results of Health CareScience, 1998
- Commission on Outcome Measurement in Epilepsy, 1994–1997: Final ReportEpilepsia, 1998
- Quality of Life of People with Epilepsy: A European StudyEpilepsia, 1997
- Patient‐Validated Content of Epilepsy‐Specific Quality‐of‐Life MeasurementEpilepsia, 1997
- Patient awareness of seizuresNeurology, 1996
- A Comparison of Valproate with Carbamazepine for the Treatment of Complex Partial Seizures and Secondarily Generalized Tonic–Clonic Seizures in AdultsNew England Journal of Medicine, 1992
- Automatic seizure detection: improvements and evaluationElectroencephalography and Clinical Neurophysiology, 1990
- Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic SeizuresNew England Journal of Medicine, 1985
- Small Area Variations in Health Care DeliveryScience, 1973